Search 

ZY Therapeutics Inc. is a venture backed startup company focusing on developing innovative precision drug delivery technology. It was founded by two scientists in 2015 in North Carolina. In 2017, ZY’s leading project won collaboration award from Nanotechnology Characterization Lab (NCL), part of national lab established by FDA, NCI and NIST in a concerted effort to regulate and support nanotechnology in oncology space. ZY’s proprietary delivery platforms currently focus on optimized injectable formulations to deliver oncology therapy to the action sites. The first biodegradable oncology nano-formulation, ZY-010-PNP, completed Pre-IND discussion with the FDA and agreement on 505b(2) regulatory pathway was achieved. Further, the isotope labeling human plasma In vitro study as well as canine pharmacokinetic study conducted by NCL suggest a unique drug releasing profile in comparison to the benchmark brands suggesting enhanced the therapeutic effect with lower safety concern. The active targeting delivery nanomedicine ZY-012-CNP for prostate cancer is in preclinic development and scheduled to file Pre-IND application in 2021. Additional products are in encapsulation feasibility studies including targeting dry eye disease and other solid tumors. The target indications cover majority of solid tumors, including but not limited to TNBC, Ovarian Cancer and mCPRC, of which xenograft in vivo models have proved the drug efficacy.
ZY has developed multiple platform technologies and related patents were filed to protect global rights. The key platform patent was awarded by USPTO in 2019. Additional patents on individual product will be filed to protect the exclusive rights. This layered IP strategy ensures a long patent life for future product.
Located in Research Triangle Park in North Carolina, ZY Therapeutics has an interdisciplinary R&D team and 4,500+ sf lab space right in the heart of the southeast bio-hub. Co-founder and CEO Dr. Jian Bao has 18 years’ experience in pharmaceutical development, from discovery to clinical development. She received PhD from University of Pittsburgh and B.S. from Beijing University, both in Chemistry. The core team has a combined decades of pharmaceutical product development experience, with veteran cross-functional team leaders. ZY has assembled an advisor board that consists of world class experts in drug delivery and oncologists from both academia and industry.
ZY Therapeutics is actively seeking funding and collaboration to further develop our platform technologies and promising candidates. We look forward to taking our nano-formulations to clinic in 2021 and beyond.

Baiyu , founded in 2005, is a pharmaceutical enterprise engaged in developing, manufacturing and distributing of high-quality pharmaceutical products and APIs. With about 1000 employees, Baiyu now has 6 subsidiaries including Golden Ginkgo Pharmaceutical Co., Ltd., Ginkgolide Pharmaceuticals Co., Ltd., Sunshine Ginkgo Agriculture Co.Ltd., Sichuan Yu Jian Pharmaceutical Co., Ltd. and Ginkgo Yukang Informatics Co.,Ltd., Ginkgo Yuda Pharmaceutical Co.,Ltd., et al.

Currently,we have 8 finished pharmaceutical products and 2 APIs on the market. Based on Quality-by-Design concept, our manufacturing sites strictly comply with cGMP and EU GMP. Ginkgolide injection, Enoxaparin sodium injection, Lansoprazole for injection are our main products.

Baiyu is growing fastly and has been awarded“National High-tech Enterprise”,“Sichuan Famous Brand”and“Enterprises with the most investment value in Chinese pharmaceutical industry”in 3 consecutive years.

The culture of kindness, Taiji and phoenix leads the way we behave and our vision is to constantly benefiting mankind to enjoy life-long well-being.